RR trades 228.8% below Wall Street's consensus target of $6.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes RR achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 2 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, Richtech Robotics Inc. Class B Common Stock (RR) has a Wall Street consensus price target of $6.00, based on estimates from 2 covering analysts. With the stock currently trading at $1.82, this represents a potential upside of +228.8%. The company has a market capitalization of $335M.
Analyst price targets range from a low of $6.00 to a high of $6.00, representing a 0% spread in expectations. The median target of $6.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 1 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 1 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, RR trades at a trailing P/E of -14.0x. Analysts expect EPS to grow -15.2% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
BRBSBlue Ridge Bankshares, Inc. | $311M | $3.46 | — | — | — | — | — |
BBOTBridgeBio Oncology Therapeutics Inc. | $664M | $8.29 | $22.00 | +165.4% | Buy | — | 3 |
MVSTMicrovast Holdings, Inc. | $356M | $1.07 | $4.80 | +348.6% | Buy | 9.7x | 6 |
NXRTNexPoint Residential Trust, Inc. | $734M | $28.94 | $26.00 | -10.2% | Hold | — | 10 |
IRBTiRobot Corporation | $2M | $0.05 | — | — | — | — | — |
BFLYButterfly Network, Inc. | $2.0B | $7.58 | $5.42 | -28.5% | Buy | — | 7 |
OUSTOuster, Inc. | $2.8B | $44.06 | $56.00 | +27.1% | Hold | — | 9 |
MBOTMicrobot Medical Inc. | $87M | $1.90 | $5.50 | +189.5% | Buy | — | 3 |
ISRGIntuitive Surgical, Inc. | $151.3B | $427.30 | $597.78 | +39.9% | Buy | 40.9x | 55 |
STRCMicroStrategy Incorporated Variable Rate Series A Perpetual Stretch Preferred Stock | $29.2B | $87.46 | $252.00 | +188.1% | Hold | 1.9x | 1 |
Quick answers to the most common questions about buying RR stock.
The consensus Wall Street price target for RR is $6, representing 228.8% upside from the current price of $1.825. With 2 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
RR has a consensus rating of "Buy" based on 2 Wall Street analysts. The rating breakdown is mixed, with 0 Hold ratings making up the largest segment. The consensus 12-month price target of $6 implies 228.8% upside from current levels.
RR's current price is $1.825 with a consensus target of $6 (228.8% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $6 for RR, while the most conservative target is $6. The consensus of $6 represents the median expectation. These targets typically reflect 12-month expectations.
RR is lightly followed, with 2 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 1 have Buy ratings, 0 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month RR stock forecast based on 2 Wall Street analysts shows a consensus price target of $6, with estimates ranging from $6 (bear case) to $6 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on RR, with a "Buy" consensus rating and $6 price target (228.8% upside). 1 of 2 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
RR analyst price targets range from $6 to $6, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $6 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.